T-cell prolymphocytic leukemia.
T-cell prolymphocytic leukemia is a rare postthymic malignancy with distinctive clinical, morphologic, immunophenotypic, and cytogenetic features. The clinical course is typically aggressive with poor response to conventional chemotherapy and short survival. Treatment with purine analogues and alemtuzumab has resulted in significantly higher response rates and improved survival. Nevertheless, responses are relatively short, and the only potential curative treatment is allogeneic stem cell transplantation. The age and comorbidities of many of the patients has limited this option, but the growing use of nonmyeloablative transplantation has now widened the patient eligibility for this approach.
Department of Haemato-Oncology, The Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey SM2 5PT, United Kingdom. claire.dearden@rmh.nhs.uk
Claire E
CE
Dearden
D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D016130:Immunophenotyping; D015461:Leukemia, Prolymphocytic, T-Cell / Q000175:diagnosis* / Q000628:therapy*; D008297:Male; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D015649:Pentostatin / Q000627:therapeutic use; D033581:Stem Cell Transplantation / Q000379:methods; D014184:Transplantation, Homologous / Q000379:methods; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D015649:Pentostatin; D000074323:Alemtuzumab